Related Experiment Video
Updated: Aug 20, 2025

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
Inclusion body myositis: from genetics to clinical trials
Sara Nagy1,2, Alaa Khan3,4, Pedro M Machado5,6
1Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK. s.nagy@ucl.ac.uk.
Abstract:
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies and is characterized by a slowly progressive disease course with asymmetric muscle weakness of predominantly the finger flexors and knee extensors. The disease leads to severe disability and most patients lose ambulation due to lack of curative or disease-modifying treatment options. Despite some genes reported to be associated with hereditary IBM (a distinct group of conditions), data on the genetic susceptibility of sporadic IBM are very limited. This review gives an overview of the disease and focuses on the current genetic knowledge and potential therapeutic implications.
Related Concept Videos
Animal Mitochondrial Genetics
Myocarditis II: Clinical Features and Diagnostic Tests
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

